secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tango Therapeutics, Inc. (TNGX)
CIK:        0001819133
Form:       8-K
Filed at:   2026-06-08T11:15:55+00:00
Accession:  0001193125-26-260679
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tango reports 92% ORR in PDAC with vopimetostat + daraxonrasib combo; plans Phase 3
--------------------------------------------------------------------------------

- 92% ORR (11/12) in PDAC with vopimetostat + daraxonrasib; 90% 6-month PFS; 100% DCR.
- 100% ORR (3/3) in NSCLC with same combination; all responses confirmed.
- Vopimetostat + zoldonrasib showed 52% ORR (14/27) in PDAC; 74% 6-month PFS; 96% DCR.
- Combinations well tolerated; no discontinuations due to AEs; no Grade 4/5 related AEs.
- Company plans Phase 3 randomized-controlled trial in front-line pancreatic cancer in 2H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819133/000119312526260679/0001193125-26-260679-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819133/000119312526260679/d158334d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-260679

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer